← Human Trials & Peer-Reviewed Studies
Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk
Plain-language guide to PMID 22723322 (2012): double-blind randomized controlled trial study of Teriparatide and Parathyroid Hormone (PTH 1-84) in 578 patients.
Key Facts
- PMID
- 22723322
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2012
- Study type
- Randomized Controlled Trial
- Authors
- Nakamura T et al. (12 authors)
- DOI
- 10.1210/jc.2011-3479
What This Study Did, in Plain Language
What Was Tested
Researchers studied Teriparatide and Parathyroid Hormone (PTH 1-84) in this randomized controlled trial publication.
Who Took Part
The abstract describes 578 patients taking part.
By PubMed's age tags, the people studied were older adults and people over 80, both men and women.
Subjects were 578 Japanese patients between the ages of 65 and 95 yr who had prevalent vertebral fracture.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and multicenter.
The patients were allocated by chance, so the Teriparatide group and the comparison group should start out alike.
As a double-blind Teriparatide study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the Teriparatide group a baseline to be compared against.
Running at several centres spread the Teriparatide study over different clinics and patient groups.
In this randomized, multicenter, double-blind, placebo-controlled trial conducted in Japan, the incidence of morphological vertebral fractures by radiographs was assessed.
What Was Measured
Topics PubMed links to this paper include Bone Density, Bone Density Conservation Agents, Endpoint Determination, Japan, Kaplan-Meier Estimate, Osteoporosis and Radiography.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Teriparatide and Parathyroid Hormone (PTH 1-84) in 578 patients.
With several hundred people or more, it is a fairly large study for this kind of research.
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2012 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Teriparatide compound page and the Parathyroid Hormone (PTH 1-84) compound page, all human trials.
Our Notes on the Compounds
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.